Navigation Links
March of Dimes awards $250,000 prize to scientists who explained human sex chromosomes
Date:5/2/2011

DENVER, CO, MAY 2, 2011 Two scientists who pioneered research on the X and Y chromosomes have been chosen to receive the 2011 March of Dimes Prize in Developmental Biology.

Patricia Ann Jacobs, OBE, DSc, FRS, professor of Human Genetics, Southampton University Medical School and co-director of Research, Wessex Regional Genetics Laboratory, Salisbury, England and David C. Page, MD, director, Whitehead Institute, investigator of the Howard Hughes Medical Institute and professor of Biology at Massachusetts Institute of Technology, Cambridge, will share this year's prize.

Patricia Ann Jacobs was the first to describe a human sex chromosome abnormality with her landmark 1959 paper on Klinefelter syndrome, a disorder involving an additional X chromosome.

David Page's studies of the Y chromosome revealed its role as a complex genetic system with many specialized functions, far beyond determining male sex.

"Taken together, the research of Patricia Ann Jacobs and David Page has expanded medicine's ability to diagnose and understand the basis of infertility and many other diseases," said Michael Katz, MD, senior vice president for Research and Global Programs at the March of Dimes.

The prize was presented today to Patricia Ann Jacobs and David Page at a gala black-tie dinner and ceremony held at the Four Seasons Hotel, here. They also delivered the Sixteenth Annual March of Dimes Prize Lecture at the Colorado Convention Center at the annual meeting of the Pediatric Academic Societies. CBS sportscaster Greg Gumbel, member of the March of Dimes national Honorary Board of Trustees, hosted the award ceremony.


'/>"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Foundation
Source:Eurekalert

Page: 1

Related medicine news :

1. LGBT health research gaps and needs: IOM report release March 31
2. JCI online early table of contents: March 23, 2011
3. Fragile X researcher honored by March of Dimes
4. March/April 2011 Annals of Family Medicine tip sheet
5. JCI online early table of contents: March 14, 2011
6. Betting During March Madness May Make the Games Less Fun
7. Revitalizing Cancer Clinical Trials -- March 21 symposium
8. March of Dimes provides $2.4 million in new funding for preterm birth research
9. JCI online early table of contents: March 7, 2011
10. Dont miss March 7 pre-registration deadline for Valencia meetings
11. Journal Chest: News briefs from the March 2011 issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... WASHINGTON, June 18 While Congressional debate is focused primarily ... many Americans remain concerned about how a mandate for private ... , , "We,re hearing politicians promise that ... to keep it. But what if the federal government ...
... , MUNDELEIN, Ill., June 18 Sysmex America today announced ... Award, presented by Premier Purchasing Partners, LP ... healthcare alliance . , , Premier contracts with ... 19 contracted suppliers to receive the Pinnacle Award. Winners are ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... possible to determine which patients run a high risk of ... in patients with minimal memory impairment. This has been shown ... Sweden. The results have been published in the most ... . "The earlier we can catch Alzheimer,s disease, the ...
... millions of people each year, with costs reaching into ... challenge, Wound Care Certified professionals are becoming a growing ... The National Alliance of Wound Care (NAWC(R)), a ... credentialed over 7000 health care professionals as WCC(R)s (Wound ...
... to Vote on Merger Agreement with Pfizer - , , ... WYE ) today announced that it has filed a definitive proxy ... Meeting of Stockholders. Among other matters, stockholders will vote on ... was announced on January 26, 2009. , , ...
Cached Medicine News:Health News:Patient Advocacy Groups Urge Greater Focus on Patients' Choice and Privacy Rights in Health-Reform Debate 2Health News:Sysmex America Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Cerebrospinal fluid shows Alzheimer's disease deterioration much earlier 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 3Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 4
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... June 11, 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced ... of its investigational non-peptide oral platelet growth,factor, ... that PROMACTA at 50-75mg once daily resulted ... and also,reduced bleeding in adult patients with ...
... Phase 1 Clinical Trial of SNS-595 in Acute,Leukemia ... June 11, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented,positive ... company's,anti-cancer product candidates, SNS-595 and SNS-032, at the ... Vienna,Austria. , Interim Results from Sunesis' Phase 1 ...
Cached Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6
... designed from the ground-up with ergonomic concerns ... and most adjustable observation tube on the ... every user can adjust the microscope to ... helps the operator maintain an upright, comfortable ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
... operates with a simple click of ... Direct the mouse cursor to the ... of the slide and the magnified ... Graphic User Interface (GUI) enables one-click ...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: